{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T10:55:08Z","timestamp":1794567308617,"version":"4.9.1"},"publisher-location":"New York, NY","reference-count":92,"publisher":"Springer New York","isbn-type":[{"value":"9781493978243","type":"print"},{"value":"9781493978250","type":"electronic"}],"license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018]]},"DOI":"10.1007\/978-1-4939-7825-0_24","type":"book-chapter","created":{"date-parts":[[2018,5,31]],"date-time":"2018-05-31T08:44:16Z","timestamp":1527756256000},"page":"525-547","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Disease Modification Through Trophic Factor Delivery"],"prefix":"10.1007","author":[{"given":"Mari","family":"Savolainen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dwaine","family":"Emerich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey H.","family":"Kordower","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,6,1]]},"reference":[{"key":"24_CR1","first-page":"16","volume":"59","author":"DC Rubinsztein","year":"1996","unstructured":"Rubinsztein DC, Leggo J, Coles R et al (1996) Phenotypic characterization of individuals with 30\u201340 CAG repeats in the Huntington disease (HD) gene reveals HD cases with 36 repeats and apparently normal elderly individuals with 36\u201339 repeats. Am J Hum Genet 59:16\u201322","journal-title":"Am J Hum Genet"},{"key":"24_CR2","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1097\/00005072-198511000-00003","volume":"44","author":"JP Vonsattel","year":"1985","unstructured":"Vonsattel JP, Myers RH, Stevens TJ et al (1985) Neuropathological classification of Huntington\u2019s disease. J Neuropathol Exp Neurol 44:559\u2013577","journal-title":"J Neuropathol Exp Neurol"},{"key":"24_CR3","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/S0306-4522(00)00008-7","volume":"97","author":"M Glass","year":"2000","unstructured":"Glass M, Dragunow M, Faull RL (2000) The pattern of neurodegeneration in Huntington\u2019s disease: a comparative study of cannabinoid, dopamine, adenosine and GABA(A) receptor alterations in the human basal ganglia in Huntington\u2019s disease. Neuroscience 97:505\u2013519","journal-title":"Neuroscience"},{"key":"24_CR4","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1111\/j.1471-4159.2010.06672.x","volume":"113","author":"I Han","year":"2010","unstructured":"Han I, You Y, Kordower JH et al (2010) Differential vulnerability of neurons in Huntington\u2019s disease: the role of cell type-specific features. J Neurochem 113:1073\u20131091","journal-title":"J Neurochem"},{"key":"24_CR5","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1093\/brain\/awl243","volume":"130","author":"LJ Tippett","year":"2007","unstructured":"Tippett LJ, Waldvogel HJ, Thomas S et al (2007) Striosomes and mood dysfunction in Huntington\u2019s disease. Brain 130:206\u2013221","journal-title":"Brain"},{"key":"24_CR6","doi-asserted-by":"publisher","first-page":"5733","DOI":"10.1073\/pnas.85.15.5733","volume":"85","author":"A Reiner","year":"1988","unstructured":"Reiner A, Albin RL, Anderson KD et al (1988) Differential loss of striatal projection neurons in Huntington disease. Proc Natl Acad Sci U S A 85:5733\u20135737","journal-title":"Proc Natl Acad Sci U S A"},{"key":"24_CR7","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.nbd.2016.08.015","volume":"96","author":"NF Mehrabi","year":"2016","unstructured":"Mehrabi NF, Waldvogel HJ, Tippett LJ et al (2016) Symptom heterogeneity in Huntington\u2019s disease correlates with neuronal degeneration in the cerebral cortex. Neurobiol Dis 96:67\u201374","journal-title":"Neurobiol Dis"},{"key":"24_CR8","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1093\/brain\/awq047","volume":"133","author":"DCV Thu","year":"2010","unstructured":"Thu DCV, Oorschot DE, Tippett LJ et al (2010) Cell loss in the motor and cingulate cortex correlates with symptomatology in Huntington\u2019s disease. Brain 133:1094\u20131110","journal-title":"Brain"},{"key":"24_CR9","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1006\/nbdi.2002.0528","volume":"10","author":"V Macdonald","year":"2002","unstructured":"Macdonald V, Halliday G (2002) Pyramidal cell loss in motor cortices in Huntington\u2019s disease. Neurobiol Dis 10:378\u2013386","journal-title":"Neurobiol Dis"},{"key":"24_CR10","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1093\/brain\/awn025","volume":"131","author":"HD Rosas","year":"2008","unstructured":"Rosas HD, Salat DH, Lee SY et al (2008) Cerebral cortex and the clinical expression of Huntington\u2019s disease: complexity and heterogeneity. Brain 131:1057\u20131068","journal-title":"Brain"},{"key":"24_CR11","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/S0140-6736(07)60111-1","volume":"369","author":"FO Walker","year":"2007","unstructured":"Walker FO (2007) Huntington\u2019s disease. Lancet 369:218\u2013228","journal-title":"Lancet"},{"key":"24_CR12","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1001\/archneur.62.1.46","volume":"62","author":"S Gunawardena","year":"2005","unstructured":"Gunawardena S, Goldstein LSB (2005) Polyglutamine diseases and transport problems: deadly traffic jams on neuronal highways. Arch Neurol 62:46\u201351","journal-title":"Arch Neurol"},{"key":"24_CR13","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1038\/nn.2528","volume":"13","author":"M Martinez-Vicente","year":"2010","unstructured":"Martinez-Vicente M, Talloczy Z, Wong E et al (2010) Cargo recognition failure is responsible for inefficient autophagy in Huntington\u2019s disease. Nat Neurosci 13:567\u2013576","journal-title":"Nat Neurosci"},{"key":"24_CR14","doi-asserted-by":"publisher","first-page":"1990","DOI":"10.1126\/science.277.5334.1990","volume":"277","author":"M DiFiglia","year":"1997","unstructured":"DiFiglia M, Sapp E, Chase KO et al (1997) Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 277:1990\u20131993","journal-title":"Science"},{"key":"24_CR15","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1038\/39885","volume":"389","author":"AC Altar","year":"1997","unstructured":"Altar AC, Cai N, Bliven T et al (1997) Anterograde transport of brain-derived neurotrophic factor and its role in the brain. Nature 389:856\u2013860","journal-title":"Nature"},{"key":"24_CR16","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1126\/science.1059581","volume":"293","author":"C Zuccato","year":"2001","unstructured":"Zuccato C, Ciammola A, Rigamonti D et al (2001) Loss of huntingtin-mediated BDNF gene transcription in Huntington\u2019s disease. Science 293:493\u2013498","journal-title":"Science"},{"key":"24_CR17","doi-asserted-by":"crossref","unstructured":"Zuccato C, Marullo M, Conforti P (2008) Systematic assessment of BDNF and its receptor levels in human cortices affected by Huntington\u2019s disease. Brain Pathol 18:225\u2013238","DOI":"10.1111\/j.1750-3639.2007.00111.x"},{"key":"24_CR18","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1111\/j.1460-9568.1994.tb01001.x","volume":"6","author":"CA Altar","year":"1994","unstructured":"Altar CA, Siuciak JA, Wright P et al (1994) In situ hybridization of trkB and trkC receptor mRNA in rat forebrain and association with high-affinity binding of [125I]BDNF, [125I]NT-4\/5 and [125I]NT-3. Eur J Neurosci 6:1389\u20131405","journal-title":"Eur J Neurosci"},{"key":"24_CR19","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1111\/j.1460-9568.2006.04590.x","volume":"23","author":"S Gin\u00e9s","year":"2006","unstructured":"Gin\u00e9s S, Bosch M, Marco S et al (2006) Reduced expression of the TrkB receptor in Huntington\u2019s disease mouse models and in human brain. Eur J Neurosci 23:649\u2013658","journal-title":"Eur J Neurosci"},{"key":"24_CR20","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.neuron.2014.05.032","volume":"83","author":"JL Plotkin","year":"2014","unstructured":"Plotkin JL, Day M, Peterson JD et al (2014) Impaired TrkB receptor signaling underlies corticostriatal dysfunction in Huntington\u2019s disease. Neuron 83:178\u2013188","journal-title":"Neuron"},{"key":"24_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2013.116","volume":"4","author":"V Brito","year":"2013","unstructured":"Brito V, Puigdell\u00edvol M, Giralt A et al (2013) Imbalance of p75(NTR)\/TrkB protein expression in Huntington\u2019s disease: implication for neuroprotective therapies. Cell Death Dis 4:e595","journal-title":"Cell Death Dis"},{"key":"24_CR22","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/nrn1726","volume":"6","author":"B Lu","year":"2005","unstructured":"Lu B, Pang PT, Woo NH (2005) The yin and yang of neurotrophin action. Nat Rev Neurosci 6:603\u2013614","journal-title":"Nat Rev Neurosci"},{"key":"24_CR23","doi-asserted-by":"publisher","first-page":"4411","DOI":"10.1172\/JCI74809","volume":"124","author":"V Brito","year":"2014","unstructured":"Brito V, Giralt A, Enriquez-Barreto L et al (2014) Neurotrophin receptor p75(NTR) mediates Huntington\u2019s disease-associated synaptic and memory dysfunction. J Clin Invest 124:4411\u20134428","journal-title":"J Clin Invest"},{"key":"24_CR24","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1002\/glia.10048","volume":"37","author":"C Dallner","year":"2002","unstructured":"Dallner C, Woods AG, Deller T et al (2002) CNTF and CNTF receptor alpha are constitutively expressed by astrocytes in the mouse brain. Glia 37:374\u2013378","journal-title":"Glia"},{"key":"24_CR25","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1002\/glia.22735","volume":"63","author":"JL Seidel","year":"2015","unstructured":"Seidel JL, Faideau M, Aiba I et al (2015) Ciliary neurotrophic factor (CNTF) activation of astrocytes decreases spreading depolarization susceptibility and increases potassium clearance. Glia 63:91\u2013103","journal-title":"Glia"},{"key":"24_CR26","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1007\/s11064-007-9514-7","volume":"33","author":"X Wang","year":"2008","unstructured":"Wang X, Zheng H, Liu C et al (2008) Ciliary neurotrophic factor-treated astrocyte conditioned medium regulates the L-type calcium channel activity in rat cortical neurons. Neurochem Res 33:826\u2013832","journal-title":"Neurochem Res"},{"key":"24_CR27","doi-asserted-by":"publisher","first-page":"7094","DOI":"10.1523\/JNEUROSCI.0174-07.2007","volume":"27","author":"C Escartin","year":"2007","unstructured":"Escartin C, Pierre K, Colin A et al (2007) Activation of astrocytes by CNTF induces metabolic plasticity and increases resistance to metabolic insults. J Neurosci 27:7094\u20137104","journal-title":"J Neurosci"},{"key":"24_CR28","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1038\/386395a0","volume":"386","author":"DF Emerich","year":"1997","unstructured":"Emerich DF, Winn SR, Hantraye PM et al (1997) Protective effect of encapsulated cells producing neurotrophic factor CNTF in a monkey model of Huntington\u2019s disease. Nature 386:395\u2013399","journal-title":"Nature"},{"key":"24_CR29","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1089\/10430340050015220","volume":"11","author":"V Mittoux","year":"2000","unstructured":"Mittoux V, Joseph JM, Conde F et al (2000) Restoration of cognitive and motor functions by ciliary neurotrophic factor in a primate model of Huntington\u2019s disease. Hum Gene Ther 11:1177\u20131187","journal-title":"Hum Gene Ther"},{"key":"24_CR30","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1089\/10430340260355383","volume":"13","author":"E R\u00e9gulier","year":"2002","unstructured":"R\u00e9gulier E, Pereira de Almeida L et al (2002) Dose-dependent neuroprotective effect of ciliary neurotrophic factor delivered via tetracycline-regulated lentiviral vectors in the quinolinic acid rat model of Huntington\u2019s disease. Hum Gene Ther 13:1981\u20131990","journal-title":"Hum Gene Ther"},{"key":"24_CR31","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1089\/10430340050111377","volume":"11","author":"AC Bachoud-L\u00e9vi","year":"2000","unstructured":"Bachoud-L\u00e9vi AC, D\u00e9glon N, Nguyen JP et al (2000) Neuroprotective gene therapy for Huntington\u2019s disease using a polymer encapsulated BHK cell line engineered to secrete human CNTF. Hum Gene Ther 11:1723\u20131729","journal-title":"Hum Gene Ther"},{"key":"24_CR32","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1089\/hum.2004.15.968","volume":"15","author":"J Bloch","year":"2004","unstructured":"Bloch J, Bachoud-L\u00e9vi AC, D\u00e9glon N et al (2004) Neuroprotective gene therapy for Huntington\u2019s disease, using polymer-encapsulated cells engineered to secrete human ciliary neurotrophic factor: results of a phase I study. Hum Gene Ther 15:968\u2013975","journal-title":"Hum Gene Ther"},{"key":"24_CR33","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/S0169-328X(99)00217-X","volume":"73","author":"TC Burazin","year":"1999","unstructured":"Burazin TC, Gundlach AL (1999) Localization of GDNF\/neurturin receptor (c-ret, GFRalpha-1 and alpha-2) mRNAs in postnatal rat brain: differential regional and temporal expression in hippocampus, cortex and cerebellum. Brain Res Mol Brain Res 73:151\u2013171","journal-title":"Brain Res Mol Brain Res"},{"key":"24_CR34","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1126\/science.8493557","volume":"260","author":"LF Lin","year":"1993","unstructured":"Lin LF, Doherty DH, Lile JD et al (1993) GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science 260:1130\u20131132","journal-title":"Science"},{"key":"24_CR35","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1038\/384467a0","volume":"384","author":"PT Kotzbauer","year":"1996","unstructured":"Kotzbauer PT, Lampe PA, Heuckeroth RO et al (1996) Neurturin, a relative of glial-cell-line-derived neurotrophic factor. Nature 384:467\u2013470","journal-title":"Nature"},{"key":"24_CR36","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1523\/JNEUROSCI.2693-11.2012","volume":"32","author":"M Hidalgo-Figueroa","year":"2012","unstructured":"Hidalgo-Figueroa M, Bonilla S, Guti\u00e9rrez F et al (2012) GDNF is predominantly expressed in the PV+ neostriatal interneuronal ensemble in normal mouse and after injury of the nigrostriatal pathway. J Neurosci 32:864\u2013872","journal-title":"J Neurosci"},{"key":"24_CR37","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1016\/S0306-4522(97)00079-1","volume":"81","author":"DM Araujo","year":"1997","unstructured":"Araujo DM, Hilt DC (1997) Glial cell line-derived neurotrophic factor attenuates the excitotoxin-induced behavioral and neurochemical deficits in a rodent model of Huntington\u2019s disease. Neuroscience 81:1099\u20131110","journal-title":"Neuroscience"},{"key":"24_CR38","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S0306-4522(97)00266-2","volume":"82","author":"DM Araujo","year":"1998","unstructured":"Araujo DM, Hilt DC (1998) Glial cell line-derived neurotrophic factor attenuates the locomotor hypofunction and striatonigral neurochemical deficits induced by chronic systemic administration of the mitochondrial toxin 3-nitropropionic acid. Neuroscience 82:117\u2013127","journal-title":"Neuroscience"},{"key":"24_CR39","doi-asserted-by":"publisher","first-page":"7346","DOI":"10.1073\/pnas.93.14.7346","volume":"93","author":"KD Anderson","year":"1996","unstructured":"Anderson KD, Panayotatos N, Corcoran TL et al (1996) Ciliary neurotrophic factor protects striatal output neurons in an animal model of Huntington disease. Proc Natl Acad Sci U S A 93:7346\u20137351","journal-title":"Proc Natl Acad Sci U S A"},{"key":"24_CR40","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/S0306-4522(97)00424-7","volume":"83","author":"BT Volpe","year":"1998","unstructured":"Volpe BT, Wildmann J, Altar CA (1998) Brain-derived neurotrophic factor prevents the loss of nigral neurons induced by excitotoxic striatal-pallidal lesions. Neuroscience 83:741\u2013748","journal-title":"Neuroscience"},{"key":"24_CR41","doi-asserted-by":"publisher","first-page":"7727","DOI":"10.1523\/JNEUROSCI.1197-04.2004","volume":"24","author":"JM Canals","year":"2004","unstructured":"Canals JM, Pineda JR, Torres-Peraza JF et al (2004) Brain-derived neurotrophic factor regulates the onset and severity of motor dysfunction associated with enkephalinergic neuronal degeneration in Huntington\u2019s disease. J Neurosci 24:7727\u20137739","journal-title":"J Neurosci"},{"key":"24_CR42","doi-asserted-by":"publisher","first-page":"1481.e1","DOI":"10.1016\/j.neurobiolaging.2011.11.030","volume":"33","author":"KJ Griffioen","year":"2012","unstructured":"Griffioen KJ, Wan R, Brown TR et al (2012) Aberrant heart rate and brainstem brain-derived neurotrophic factor (BDNF) signaling in a mouse model of Huntington\u2019s disease. Neurobiol Aging 33:1481.e1\u20131481.e5","journal-title":"Neurobiol Aging"},{"key":"24_CR43","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0064037","volume":"8","author":"C Giamp\u00e0","year":"2013","unstructured":"Giamp\u00e0 C, Montagna E, Dato C et al (2013) Systemic delivery of recombinant brain derived neurotrophic factor (BDNF) in the R6\/2 mouse model of Huntington\u2019s disease. PLoS One 8:e64037","journal-title":"PLoS One"},{"key":"24_CR44","doi-asserted-by":"publisher","first-page":"5168","DOI":"10.1523\/JNEUROSCI.16-16-05168.1996","volume":"16","author":"DF Emerich","year":"1996","unstructured":"Emerich DF, Lindner MD, Winn SR et al (1996) Implants of encapsulated human CNTF-producing fibroblasts prevent behavioral deficits and striatal degeneration in a rodent model of Huntington\u2019s disease. J Neurosci 16:5168\u20135181","journal-title":"J Neurosci"},{"key":"24_CR45","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1177\/096368979800700215","volume":"7","author":"DF Emerich","year":"1998","unstructured":"Emerich DF, Bruhn S, Chu Y, Kordower JH (1998) Cellular delivery of CNTF but not NT-4\/5 prevents degeneration of striatal neurons in a rodent model of Huntington\u2019s disease. Cell Transplant 7:213\u2013225","journal-title":"Cell Transplant"},{"key":"24_CR46","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.expneurol.2004.12.009","volume":"193","author":"N Popovic","year":"2005","unstructured":"Popovic N, Maingay M, Kirik D, Brundin P (2005) Lentiviral gene delivery of GDNF into the striatum of R6\/2 Huntington mice fails to attenuate behavioral and neuropathological changes. Exp Neurol 193:65\u201374","journal-title":"Exp Neurol"},{"key":"24_CR47","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1002\/jnr.21636","volume":"86","author":"EM Denovan-Wright","year":"2008","unstructured":"Denovan-Wright EM, Attis M, Rodriguez-Lebron E, Mandel RJ (2008) Sustained striatal ciliary neurotrophic factor expression negatively affects behavior and gene expression in normal and R6\/1 mice. J Neurosci Res 86:1748\u20131757","journal-title":"J Neurosci Res"},{"key":"24_CR48","doi-asserted-by":"publisher","first-page":"9345","DOI":"10.1073\/pnas.0508875103","volume":"103","author":"JL McBride","year":"2006","unstructured":"McBride JL, Ramaswamy S, Gasmi M et al (2006) Viral delivery of glial cell line-derived neurotrophic factor improves behavior and protects striatal neurons in a mouse model of Huntington\u2019s disease. Proc Natl Acad Sci U S A 103:9345\u20139350","journal-title":"Proc Natl Acad Sci U S A"},{"key":"24_CR49","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.nbd.2008.12.005","volume":"34","author":"S Ramaswamy","year":"2009","unstructured":"Ramaswamy S, McBride JL, Han I et al (2009) Intrastriatal CERE-120 (AAV-Neurturin) protects striatal and cortical neurons and delays motor deficits in a transgenic mouse model of Huntington\u2019s disease. Neurobiol Dis 34:40\u201350","journal-title":"Neurobiol Dis"},{"key":"24_CR50","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.expneurol.2003.09.002","volume":"185","author":"D Zala","year":"2004","unstructured":"Zala D, Bensadoun J-C, Pereira de Almeida L et al (2004) Long-term lentiviral-mediated expression of ciliary neurotrophic factor in the striatum of Huntington\u2019s disease transgenic mice. Exp Neurol 185:26\u201335","journal-title":"Exp Neurol"},{"key":"24_CR51","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/S0014-4886(03)00044-X","volume":"181","author":"JL McBride","year":"2003","unstructured":"McBride JL, During MJ, Wuu J et\u00a0al (2003) Structural and functional neuroprotection in a rat model of Huntington\u2019s disease by viral gene transfer of GDNF. Exp Neurol 181:213\u2013223","journal-title":"Exp Neurol"},{"key":"24_CR52","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.nbd.2007.01.003","volume":"26","author":"S Ramaswamy","year":"2007","unstructured":"Ramaswamy S, McBride JL, Herzog CD et al (2007) Neurturin gene therapy improves motor function and prevents death of striatal neurons in a 3-nitropropionic acid rat model of Huntington\u2019s disease. Neurobiol Dis 26:375\u2013384","journal-title":"Neurobiol Dis"},{"key":"24_CR53","doi-asserted-by":"publisher","first-page":"4478","DOI":"10.1523\/JNEUROSCI.22-11-04478.2002","volume":"22","author":"V Mittoux","year":"2002","unstructured":"Mittoux V, Ouary S, Monville C et al (2002) Corticostriatopallidal neuroprotection by adenovirus-mediated ciliary neurotrophic factor gene transfer in a rat model of progressive striatal degeneration. J Neurosci 22:4478\u20134486","journal-title":"J Neurosci"},{"key":"24_CR54","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/j.ymthe.2004.02.016","volume":"9","author":"AP Kells","year":"2004","unstructured":"Kells AP, Fong DM, Dragunow M et al (2004) AAV-mediated gene delivery of BDNF or GDNF is neuroprotective in a model of Huntington disease. Mol Ther 9:682\u2013688","journal-title":"Mol Ther"},{"key":"24_CR55","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1038\/gt.2008.23","volume":"15","author":"AP Kells","year":"2008","unstructured":"Kells AP, Henry RA, Connor B (2008) AAV-BDNF mediated attenuation of quinolinic acid-induced neuropathology and motor function impairment. Gene Ther 15:966\u2013977","journal-title":"Gene Ther"},{"key":"24_CR56","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/0142-9612(96)85563-3","volume":"17","author":"KE Dionne","year":"1996","unstructured":"Dionne KE, Cain BM, Li RH et al (1996) Transport characterization of membranes for immunoisolation. Biomaterials 17:257\u2013266","journal-title":"Biomaterials"},{"key":"24_CR57","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/0014-4886(91)90093-R","volume":"111","author":"P Aebischer","year":"1991","unstructured":"Aebischer P, Tresco PA, Winn SR et al (1991) Long-term cross-species brain transplantation of a polymer-encapsulated dopamine-secreting cell line. Exp Neurol 111:269\u2013275","journal-title":"Exp Neurol"},{"key":"24_CR58","first-page":"21","volume":"11","author":"MD Lindner","year":"1997","unstructured":"Lindner MD, Plone MA, Frydel B et al (1997) Intraventricular encapsulated calf adrenal chromaffin cells: viable for at least 500 days in vivo without detectable adverse effects on behavioral\/cognitive function or host immune sensitization in rats. Restor Neurol Neurosci 11:21\u201335","journal-title":"Restor Neurol Neurosci"},{"key":"24_CR59","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.addr.2013.07.008","volume":"67\u201368","author":"DF Emerich","year":"2014","unstructured":"Emerich DF, Orive G, Thanos C et al (2014) Encapsulated cell therapy for neurodegenerative diseases: from promise to product. Adv Drug Deliv Rev 67\u201368:131\u2013141","journal-title":"Adv Drug Deliv Rev"},{"key":"24_CR60","doi-asserted-by":"publisher","first-page":"2164","DOI":"10.1038\/mt.2010.154","volume":"18","author":"L Fjord-Larsen","year":"2010","unstructured":"Fjord-Larsen L, Kusk P, Torn\u00f8e J et\u00a0al (2010) Long-term delivery of nerve growth factor by encapsulated cell biodelivery in the G\u00f6ttingen minipig basal forebrain. Mol Ther 18:2164\u20132172","journal-title":"Mol Ther"},{"key":"24_CR61","doi-asserted-by":"publisher","first-page":"340","DOI":"10.3171\/2012.2.JNS11714","volume":"117","author":"LU Wahlberg","year":"2012","unstructured":"Wahlberg LU, Lind G, Almqvist PM et al (2012) Targeted delivery of nerve growth factor via encapsulated cell biodelivery in Alzheimer disease: a technology platform for restorative neurosurgery. J Neurosurg 117:340\u2013347","journal-title":"J Neurosurg"},{"key":"24_CR62","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1038\/gt.2011.178","volume":"19","author":"L Fjord-Larsen","year":"2012","unstructured":"Fjord-Larsen L, Kusk P, Emerich DF et al (2012) Increased encapsulated cell biodelivery of nerve growth factor in the brain by transposon-mediated gene transfer. Gene Ther 19:1010\u20131017","journal-title":"Gene Ther"},{"key":"24_CR63","doi-asserted-by":"publisher","first-page":"517","DOI":"10.4155\/tde.10.50","volume":"1","author":"SJ Gray","year":"2010","unstructured":"Gray SJ, Woodard KT, Samulski RJ (2010) Viral vectors and delivery strategies for CNS gene therapy. Ther Deliv 1:517\u2013534","journal-title":"Ther Deliv"},{"key":"24_CR64","doi-asserted-by":"publisher","first-page":"299","DOI":"10.2174\/1566523054064968","volume":"5","author":"VW Choi","year":"2005","unstructured":"Choi VW, McCarty DM, Samulski RJ (2005) AAV hybrid serotypes: improved vectors for gene delivery. Curr Gene Ther 5:299\u2013310","journal-title":"Curr Gene Ther"},{"key":"24_CR65","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1038\/mt.2010.106","volume":"18","author":"P Hadaczek","year":"2010","unstructured":"Hadaczek P, Eberling JL, Pivirotto P et al (2010) Eight years of clinical improvement in MPTP-lesioned primates after gene therapy with AAV2-hAADC. Mol Ther 18:1458\u20131461","journal-title":"Mol Ther"},{"key":"24_CR66","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1126\/science.290.5492.767","volume":"290","author":"JH Kordower","year":"2000","unstructured":"Kordower JH, Emborg ME, Bloch J et\u00a0al (2000) Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson\u2019s disease. Science 290:767\u2013773","journal-title":"Science"},{"key":"24_CR67","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1006\/mthe.2000.0224","volume":"3","author":"CE Thomas","year":"2001","unstructured":"Thomas CE, Birkett D, Anozie I et al (2001) Acute direct adenoviral vector cytotoxicity and chronic, but not acute, inflammatory responses correlate with decreased vector-mediated transgene expression in the brain. Mol Ther 3:36\u201346","journal-title":"Mol Ther"},{"key":"24_CR68","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0076310","volume":"8","author":"DF Aschauer","year":"2013","unstructured":"Aschauer DF, Kreuz S, Rumpel S (2013) Analysis of transduction efficiency, tropism and axonal transport of AAV serotypes 1, 2, 5, 6, 8 and 9 in the mouse brain. PLoS One 8:e76310","journal-title":"PLoS One"},{"key":"24_CR69","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1038\/nn.2346","volume":"12","author":"GA Morfini","year":"2009","unstructured":"Morfini GA, You Y-M, Pollema SL et al (2009) Pathogenic huntingtin inhibits fast axonal transport by activating JNK3 and phosphorylating kinesin. Nat Neurosci 12:864\u2013871","journal-title":"Nat Neurosci"},{"key":"24_CR70","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1126\/science.1105681","volume":"307","author":"GB Stokin","year":"2005","unstructured":"Stokin GB, Lillo C, Falzone TL et al (2005) Axonopathy and transport deficits early in the pathogenesis of Alzheimer\u2019s disease. Science 307:1282\u20131288","journal-title":"Science"},{"key":"24_CR71","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.1093\/brain\/aws133","volume":"135","author":"Y Chu","year":"2012","unstructured":"Chu Y, Morfini GA, Langhamer LB et al (2012) Alterations in axonal transport motor proteins in sporadic and experimental Parkinson\u2019s disease. Brain 135:2058\u20132073","journal-title":"Brain"},{"key":"24_CR72","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/S0896-6273(03)00569-5","volume":"40","author":"G Szebenyi","year":"2003","unstructured":"Szebenyi G, Morfini GA, Babcock A et al (2003) Neuropathogenic forms of huntingtin and androgen receptor inhibit fast axonal transport. Neuron 40:41\u201352","journal-title":"Neuron"},{"key":"24_CR73","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1002\/mds.23442","volume":"26","author":"RT Bartus","year":"2011","unstructured":"Bartus RT, Herzog CD, Chu Y et al (2011) Bioactivity of AAV2-neurturin gene therapy (CERE-120): differences between Parkinson\u2019s disease and nonhuman primate brains. Mov Disord 26:27\u201336","journal-title":"Mov Disord"},{"key":"24_CR74","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1016\/S1474-4422(10)70254-4","volume":"9","author":"WJ Marks Jr","year":"2010","unstructured":"Marks WJ Jr, Bartus RT, Siffert J et\u00a0al (2010) Gene delivery of AAV2-neurturin for Parkinson\u2019s disease: a double-blind, randomised, controlled trial. Lancet Neurol 9:1164\u20131172","journal-title":"Lancet Neurol"},{"key":"24_CR75","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1002\/ana.24436","volume":"78","author":"WC Olanow","year":"2015","unstructured":"Olanow WC, Bartus RT, Baumann TL et al (2015) Gene delivery of neurturin to putamen and substantia nigra in Parkinson disease: a double-blind, randomized, controlled trial. Ann Neurol 78:248\u2013257","journal-title":"Ann Neurol"},{"key":"24_CR76","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1089\/hum.2006.178","volume":"18","author":"J-M Taymans","year":"2007","unstructured":"Taymans J-M, Vandenberghe LH, Haute CVD et al (2007) Comparative analysis of adeno-associated viral vector serotypes 1, 2, 5, 7, and 8 in mouse brain. Hum Gene Ther 18:195\u2013206","journal-title":"Hum Gene Ther"},{"key":"24_CR77","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.ymthe.2004.05.024","volume":"10","author":"C Burger","year":"2004","unstructured":"Burger C, Gorbatyuk OS, Velardo MJ et al (2004) Recombinant AAV viral vectors pseudotyped with viral capsids from serotypes 1, 2, and 5 display differential efficiency and cell tropism after delivery to different regions of the central nervous system. Mol Ther 10:302\u2013317","journal-title":"Mol Ther"},{"key":"24_CR78","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1038\/mt.2009.286","volume":"18","author":"EA Markakis","year":"2010","unstructured":"Markakis EA, Vives KP, Bober J et\u00a0al (2010) Comparative transduction efficiency of AAV vector serotypes 1\u20136 in the substantia nigra and striatum of the primate brain. Mol Ther 18:588\u2013593","journal-title":"Mol Ther"},{"key":"24_CR79","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1038\/mt.2009.216","volume":"18","author":"HB Dodiya","year":"2010","unstructured":"Dodiya HB, Bj\u00f6rklund T, Stansell J et\u00a0al (2010) Differential transduction following basal ganglia administration of distinct pseudotyped AAV capsid serotypes in nonhuman primates. Mol Ther 18:579\u2013587","journal-title":"Mol Ther"},{"key":"24_CR80","doi-asserted-by":"publisher","first-page":"16037","DOI":"10.1038\/mtm.2016.37","volume":"3","author":"P Hadaczek","year":"2016","unstructured":"Hadaczek P, Stanek L, Ciesielska A et al (2016) Widespread AAV1- and AAV2-mediated transgene expression in the nonhuman primate brain: implications for Huntington\u2019s disease. Mol Ther Methods Clin Dev 3:16037","journal-title":"Mol Ther Methods Clin Dev"},{"key":"24_CR81","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1038\/mt.2008.100","volume":"16","author":"W Li","year":"2008","unstructured":"Li W, Asokan A, Wu Z et al (2008) Engineering and selection of shuffled AAV genomes: a new strategy for producing targeted biological nanoparticles. Mol Ther 16:1252\u20131260","journal-title":"Mol Ther"},{"key":"24_CR82","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1002\/(SICI)1096-9071(199911)59:3<406::AID-JMV22>3.0.CO;2-N","volume":"59","author":"K Erles","year":"1999","unstructured":"Erles K, Seb\u00f6kov\u00e0 P, Schlehofer JR (1999) Update on the prevalence of serum antibodies (IgG and IgM) to adeno-associated virus (AAV). J Med Virol 59:406\u2013411","journal-title":"J Med Virol"},{"key":"24_CR83","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1038\/sj.gt.3300994","volume":"6","author":"N Chirmule","year":"1999","unstructured":"Chirmule N, Propert K, Magosin S et al (1999) Immune responses to adenovirus and adeno-associated virus in humans. Gene Ther 6:1574\u20131583","journal-title":"Gene Ther"},{"key":"24_CR84","doi-asserted-by":"publisher","first-page":"6344","DOI":"10.1128\/JVI.78.12.6344-6359.2004","volume":"78","author":"CS Peden","year":"2004","unstructured":"Peden CS, Burger C, Muzyczka N, Mandel RJ (2004) Circulating anti-wild-type adeno-associated virus type 2 (AAV2) antibodies inhibit recombinant AAV2 (rAAV2)-mediated, but not rAAV5-mediated, gene transfer in the brain. J Virol 78:6344\u20136359","journal-title":"J Virol"},{"key":"24_CR85","doi-asserted-by":"publisher","first-page":"6456","DOI":"10.1073\/pnas.94.12.6456","volume":"94","author":"I Gloaguen","year":"1997","unstructured":"Gloaguen I, Costa P, Demartis A et al (1997) Ciliary neurotrophic factor corrects obesity and diabetes associated with leptin deficiency and resistance. Proc Natl Acad Sci U S A 94:6456\u20136461","journal-title":"Proc Natl Acad Sci U S A"},{"key":"24_CR86","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1126\/science.1115360","volume":"310","author":"MV Kokoeva","year":"2005","unstructured":"Kokoeva MV, Yin H, Flier JS (2005) Neurogenesis in the hypothalamus of adult mice: potential role in energy balance. Science 310:679\u2013683","journal-title":"Science"},{"key":"24_CR87","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/S0092-8674(00)81369-0","volume":"87","author":"L Mangiarini","year":"1996","unstructured":"Mangiarini L, Sathasivam K, Seller M et al (1996) Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 87:493\u2013506","journal-title":"Cell"},{"key":"24_CR88","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1089\/hum.2015.134","volume":"27","author":"WJ Marks Jr","year":"2016","unstructured":"Marks WJ Jr, Baumann TL, Bartus RT (2016) Long-term safety of patients with Parkinson\u2019s disease receiving rAAV2-neurturin (CERE-120) gene transfer. Hum Gene Ther 27:522\u2013527","journal-title":"Hum Gene Ther"},{"key":"24_CR89","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.nbd.2016.03.026","volume":"97","author":"RT Bartus","year":"2017","unstructured":"Bartus RT, Johnson EM Jr (2017) Clinical tests of neurotrophic factors for human neurodegenerative diseases: Part 2. Where do we stand and where must we go next? Neurobiol Dis 97:169\u2013178","journal-title":"Neurobiol Dis"},{"key":"24_CR90","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1038\/nature06975","volume":"453","author":"S-H Yang","year":"2008","unstructured":"Yang S-H, Cheng P-H, Banta H et al (2008) Towards a transgenic model of Huntington\u2019s disease in a non-human primate. Nature 453:921\u2013924","journal-title":"Nature"},{"key":"24_CR91","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/1471-2202-15-36","volume":"15","author":"AW Chan","year":"2014","unstructured":"Chan AW, Xu Y, Jiang J et\u00a0al (2014) A two years longitudinal study of a transgenic Huntington disease monkey. BMC Neurosci 15:36","journal-title":"BMC Neurosci"},{"key":"24_CR92","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0122335","volume":"10","author":"AWS Chan","year":"2015","unstructured":"Chan AWS, Jiang J, Chen Y et al (2015) Progressive cognitive deficit, motor impairment and striatal pathology in a transgenic Huntington disease monkey model from infancy to adulthood. PLoS One 10:e0122335","journal-title":"PLoS One"}],"container-title":["Methods in Molecular Biology","Huntington\u2019s Disease"],"original-title":[],"link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-4939-7825-0_24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,7]],"date-time":"2024-07-07T01:50:14Z","timestamp":1720317014000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/978-1-4939-7825-0_24"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018]]},"ISBN":["9781493978243","9781493978250"],"references-count":92,"URL":"https:\/\/doi.org\/10.1007\/978-1-4939-7825-0_24","relation":{"is-part-of":[{"id-type":"doi","id":"https:\/\/doi.org\/10.1007\/978-1-4939-7825-0","asserted-by":"object"}]},"ISSN":["1064-3745","1940-6029"],"issn-type":[{"value":"1064-3745","type":"print"},{"value":"1940-6029","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018]]}}}